Stocktoria
Outlook Therapeutics, Inc. OTLK
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2016-06-13
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $1.4M | — | — | — | — |
| Gross profit | $57,205 | — | — | — | — |
| Operating income | -$67.1M | -$71.7M | -$53.1M | -$63.1M | -$51.7M |
| Net income | -$62.4M | -$75.4M | -$59.0M | -$66.1M | -$53.2M |
| Operating cash flow | -$51.8M | -$68.8M | -$43.0M | -$56.7M | -$54.3M |
| Total assets | $18.6M | $28.8M | $32.3M | $28.5M | $22.8M |
| Total liabilities | $50.8M | $101.9M | $46.7M | $19.8M | $18.2M |
| Shareholders' equity | -$32.2M | -$73.1M | -$14.4M | $8.7M | $4.6M |
| Ratios | |||||
| Gross margin | 4.0% | — | — | — | — |
| Operating margin | -4744.3% | — | — | — | — |
| Net margin | -4416.2% | — | — | — | — |
| Return on assets | -335.9% | -261.5% | -182.6% | -231.5% | -233.1% |
| Return on equity | 193.9% | 103.1% | 408.5% | -756.0% | -1153.9% |
| Current ratio | 0.38 | 0.64 | 0.66 | 1.39 | 3.19 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 255,157 | $52,511 |
| Point72 Asset Management, L.P. | 29,038 | $5,976 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001649989 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.